Galleri by GRAIL vs Oncotype DX

Side-by-side comparison of cancer screening tests.

← Back to Cancer Screening

Galleri by GRAIL

Not FDA approved
$949

50+ cancers

Oncotype DX

Guideline recommended
Variable

Breast recurrence risk

Test Performance

FeatureGalleri by GRAILOncotype DX
Price$949Variable
Cancers Detected50+ cancersBreast recurrence risk
Sensitivity51.5% overallN/A
Specificity99.5%N/A
Sample TypeBlood drawTumor tissue
FDA StatusNot FDA approvedGuideline recommended